Short Interest in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Grows By 80.0%

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a large growth in short interest in September. As of September 15th, there was short interest totalling 364,600 shares, a growth of 80.0% from the August 31st total of 202,500 shares. Based on an average trading volume of 5,550,000 shares, the days-to-cover ratio is currently 0.1 days.

CNS Pharmaceuticals Stock Performance

Shares of NASDAQ:CNSP remained flat at $0.14 during midday trading on Friday. 670,562 shares of the company traded hands, compared to its average volume of 2,014,493. CNS Pharmaceuticals has a twelve month low of $0.10 and a twelve month high of $137.50. The business has a 50 day moving average of $0.28 and a 200-day moving average of $6.04. The firm has a market capitalization of $203,318.70, a P/E ratio of 0.00 and a beta of 2.58.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its earnings results on Wednesday, August 14th. The company reported ($6.72) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Maxim Group raised shares of CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Tuesday, September 10th.

Hedge Funds Weigh In On CNS Pharmaceuticals

A hedge fund recently raised its stake in CNS Pharmaceuticals stock. Virtu Financial LLC boosted its stake in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) by 616.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,246 shares of the company’s stock after purchasing an additional 81,094 shares during the quarter. Virtu Financial LLC owned about 0.80% of CNS Pharmaceuticals worth $34,000 at the end of the most recent reporting period. Institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.